304 related articles for article (PubMed ID: 12504547)
1. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
Kim YB; Han DP; Cao C; Cho MW
Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
[TBL] [Abstract][Full Text] [Related]
2. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
[TBL] [Abstract][Full Text] [Related]
4. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
Srivastava IK; VanDorsten K; Vojtech L; Barnett SW; Stamatatos L
J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
[TBL] [Abstract][Full Text] [Related]
5. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
Ching L; Stamatatos L
J Virol; 2010 Oct; 84(19):9932-46. PubMed ID: 20660181
[TBL] [Abstract][Full Text] [Related]
6. Neutralization epitopes of the HIV-1 primary isolate DH012.
Zhu C; Matthews TJ; Chen CH
Vaccine; 2003 Jul; 21(23):3301-6. PubMed ID: 12804861
[TBL] [Abstract][Full Text] [Related]
7. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
[TBL] [Abstract][Full Text] [Related]
8. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
[TBL] [Abstract][Full Text] [Related]
9. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
10. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.
Law M; Cardoso RM; Wilson IA; Burton DR
J Virol; 2007 Apr; 81(8):4272-85. PubMed ID: 17267498
[TBL] [Abstract][Full Text] [Related]
11. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
[TBL] [Abstract][Full Text] [Related]
12. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
[TBL] [Abstract][Full Text] [Related]
14. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
15. Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits.
Qin Y; Shi H; Banerjee S; Agrawal A; Banasik M; Cho MW
Retrovirology; 2014 Dec; 11():125. PubMed ID: 25527085
[TBL] [Abstract][Full Text] [Related]
16. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
[TBL] [Abstract][Full Text] [Related]
17. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein.
Kelker HC; Itri VR; Valentine FT
PLoS One; 2010 Jan; 5(1):e8555. PubMed ID: 20052405
[TBL] [Abstract][Full Text] [Related]
18. Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies.
Neurath AR; Strick N; Fields R; Jiang S
AIDS Res Hum Retroviruses; 1991 Aug; 7(8):657-62. PubMed ID: 1718344
[TBL] [Abstract][Full Text] [Related]
19. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
[TBL] [Abstract][Full Text] [Related]
20. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
Gzyl J; Bolesta E; Wierzbicki A; Kmieciak D; Naito T; Honda M; Komuro K; Kaneko Y; Kozbor D
Virology; 2004 Jan; 318(2):493-506. PubMed ID: 14972518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
